AT Bancorp trimmed its position in CVS Health Corp (NYSE:CVS) by 59.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,119 shares of the pharmacy operator’s stock after selling 13,440 shares during the quarter. AT Bancorp’s holdings in CVS Health were worth $661,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Calton & Associates Inc. acquired a new position in CVS Health during the 4th quarter valued at $636,000. Aveo Capital Partners LLC acquired a new position in CVS Health during the 4th quarter valued at $201,000. Mork Capital Management LLC acquired a new position in CVS Health during the 4th quarter valued at $993,000. Raymond James Trust N.A. raised its stake in CVS Health by 1.4% during the 4th quarter. Raymond James Trust N.A. now owns 129,450 shares of the pharmacy operator’s stock valued at $9,385,000 after purchasing an additional 1,843 shares during the last quarter. Finally, Delaney Dennis R raised its stake in CVS Health by 44.1% during the 4th quarter. Delaney Dennis R now owns 31,455 shares of the pharmacy operator’s stock valued at $2,280,000 after purchasing an additional 9,620 shares during the last quarter. Institutional investors and hedge funds own 83.96% of the company’s stock.

How to Become a New Pot Stock Millionaire

CVS Health Corp (NYSE CVS) opened at $61.79 on Friday. CVS Health Corp has a one year low of $61.74 and a one year high of $84.00. The stock has a market cap of $63,854.64, a price-to-earnings ratio of 9.55, a PEG ratio of 1.04 and a beta of 1.03. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The company had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. During the same quarter in the prior year, the company posted $1.71 EPS. The business’s revenue was up 5.3% on a year-over-year basis. sell-side analysts forecast that CVS Health Corp will post 6.37 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Friday, April 20th. CVS Health’s dividend payout ratio is 30.91%.

In other news, EVP Helena Foulkes sold 19,965 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $71.04, for a total value of $1,418,313.60. Following the sale, the executive vice president now owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.61% of the stock is currently owned by corporate insiders.

Several research firms recently commented on CVS. ValuEngine cut shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Vetr cut shares of CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price for the company. in a research note on Thursday, January 4th. SunTrust Banks upped their target price on shares of CVS Health to $90.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Morgan Stanley upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price for the company in a research note on Friday, January 5th. Finally, Robert W. Baird set a $77.00 target price on shares of CVS Health and gave the company a “hold” rating in a research note on Monday, December 4th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $87.03.

TRADEMARK VIOLATION WARNING: “AT Bancorp Has $661,000 Stake in CVS Health Corp (CVS)” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/at-bancorp-has-661000-stake-in-cvs-health-corp-cvs/1958933.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.